Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Doctor-Created Device Turns To Crowdfunding

This article was originally published in The Gray Sheet

Executive Summary

The Omni-Pro “14-in-one” integrates a range of common exam-room tools into a stethoscope-mounted unit. It has raised $6,000 on crowdfunding site Indiegogo since March 20.

You may also be interested in...

Biosense Modifies Urinalysis App To Comply With FDA

The app developer unveiled its plans to comply with FDA regulations for its uChek urinalysis app, including the submission of a 510(k) for the full-feature product and launch of a Lite version. FDA sent a letter to Biosense questioning its earlier launch of the app without a 510(k) after an article ran in “The Gray Sheet” assessing its regulatory status.

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts